121 related articles for article (PubMed ID: 3403059)
1. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
[TBL] [Abstract][Full Text] [Related]
2. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic plasmapheresis for post-operative hepatic failure.
Tani T; Endo Y; Yoshioka T; Aoki H; Matsuda K; Numa K; Hanasawa K; Kodama M
Prog Clin Biol Res; 1990; 337():213-20. PubMed ID: 2352979
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
5. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
Hosokawa S; Oyamaguchi A; Yoshida O
ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
9. Nafamostat mesilate reduces blood loss during open heart surgery.
Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
[TBL] [Abstract][Full Text] [Related]
10. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of FUT-175 anticoagulant in adsorbent plasma perfusion.
Yamazaki Z; Hiraishi M; Kanai F; Takahama T; Idezuki Y; Inoue N
ASAIO Trans; 1989; 35(3):567-9. PubMed ID: 2688721
[TBL] [Abstract][Full Text] [Related]
12. Experimental results using nafamostat mesilate as anticoagulant during extracorporeal lung assist for 24 hours in dogs.
Okamoto T; Chung YK; Choi H; Terasaki H; Morioka T
Artif Organs; 1993 Jan; 17(1):30-6. PubMed ID: 8422232
[TBL] [Abstract][Full Text] [Related]
13. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
[TBL] [Abstract][Full Text] [Related]
14. The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.
Wisner JR; Ozawa S; Renner IG
Int J Pancreatol; 1989 May; 4(4):383-90. PubMed ID: 2732529
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis.
Dobosz M; Sledzinski Z; Juszkiewicz P; Babicki A; Stanek A; Wajda Z; Basinski A
Hepatogastroenterology; 1991 Apr; 38(2):139-42. PubMed ID: 1855771
[TBL] [Abstract][Full Text] [Related]
16. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of nafamostat mesilate on the performance of a hybrid-artificial liver using a polyurethane foam/porcine hepatocyte spheroid culture system in human plasma.
Yamashita Y; Shimada M; Tsujita E; Rikimaru T; Ijima H; Nakazawa K; Sakiyama R; Fukuda J; Funatsu K; Sugimachi K
Int J Artif Organs; 2001 Jan; 24(1):34-40. PubMed ID: 11266040
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs.
Choi JH; Byun SY; Nam A; Han SM; Lee KP; Song KH; Youn HY; Seo KW
J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):122-129. PubMed ID: 29419934
[TBL] [Abstract][Full Text] [Related]
20. Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs.
Satake K; Ha S; Hiura A; Nishiwaki H; Haku A; Umeyama K
Gastroenterol Jpn; 1990 Dec; 25(6):720-6. PubMed ID: 2279634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
